Sarcoidosis

Sarcoidosis is a multisystem granulomatous disorder of unknown cause, characterized by non-caseating granulomas that most often involve the lungs and intrathoracic lymph nodes but can affect almost any organ. Its course is highly variable, ranging from spontaneous resolution to chronic, progressive disease.

Definition

Sarcoidosis is a systemic granulomatous disease of unknown etiology defined by the presence of non-caseating epithelioid granulomas in affected tissues, with frequent involvement of the lungs and intrathoracic lymph nodes, diagnosed by compatible findings together with exclusion of other granulomatous diseases.

Scope

This entry covers sarcoidosis as a granulomatous interstitial and parenchymal lung disease: its non-caseating granuloma pathology, presumed immune pathogenesis, characteristic intrathoracic involvement, and its standing as a diagnosis of exclusion. It is a reference and educational overview and does not provide individualized diagnostic or treatment guidance.

Key concepts

• Non-caseating granuloma
• Multisystem involvement
• Bilateral hilar lymphadenopathy
• Diagnosis of exclusion
• Th1-skewed immune response
• Lofgren syndrome
• Radiographic staging of intrathoracic disease
• Spontaneous remission versus chronic disease

Mechanisms

Sarcoidosis is thought to arise when an as-yet-unidentified antigen, in a genetically susceptible host, triggers an exaggerated cell-mediated, T-helper-1-skewed immune response. Activated macrophages and lymphocytes aggregate into compact, non-caseating epithelioid granulomas, the histologic hallmark of the disease. In the lung these granulomas distribute along lymphatic routes and can resolve or, in a subset, drive progressive interstitial fibrosis. Because granulomas can form in nearly any organ, the clinical picture is heterogeneous, and the absence of necrosis helps distinguish the granulomas from those of infections such as tuberculosis.

Clinical relevance

Sarcoidosis is clinically important as a great mimic: it can present in the chest or in extrapulmonary sites, and recognizing its granulomatous pattern while excluding infection and other causes is central to how it is conceptualized. This entry describes the disease for reference and education and does not offer diagnostic criteria or treatment recommendations for individuals, which remain the province of qualified clinicians.

Epidemiology

Sarcoidosis occurs worldwide with marked variation in frequency and severity by geography, sex, and ancestry, and it often presents in early to mid adulthood. Lofgren syndrome, an acute presentation with bilateral hilar lymphadenopathy, erythema nodosum, and arthralgia, is associated with a favorable prognosis, whereas other presentations may follow a chronic or progressive course.

Evidence & guidelines

The 1999 ATS/ERS/WASOG statement provided a long-standing reference framework for the definition, diagnosis, and assessment of sarcoidosis, and the 2021 ERS clinical practice guidelines addressed contemporary treatment questions. Comprehensive reviews such as Iannuzzi and colleagues (2007) and Valeyre and colleagues (2014) synthesize the disease's pathogenesis and clinical spectrum. These are cited as evidence landmarks, not as treatment instructions.

History

Described in the late nineteenth and early twentieth centuries through dermatologic and systemic observations associated with names such as Besnier, Boeck, and Schaumann, sarcoidosis was gradually recognized as a single multisystem granulomatous disease. International collaboration culminated in the 1999 joint ATS/ERS/WASOG statement, which standardized its definition and diagnostic approach, with later guidelines refining assessment and treatment.

Debates

What triggers sarcoidosis?

The etiology remains unknown; hypotheses center on an antigenic trigger, possibly microbial or environmental, interacting with host genetic susceptibility to provoke the granulomatous response, but no single cause has been confirmed.

Key figures

• Robert Baughman
• Dominique Valeyre
• Marjolein Drent
• Michael Iannuzzi

Seminal works

• ats-1999-statement
• iannuzzi-2007
• valeyre-2014-lancet

Frequently asked questions

What is a non-caseating granuloma?

It is a compact cluster of immune cells, chiefly epithelioid macrophages and lymphocytes, that lacks the central necrosis seen in caseating granulomas; it is the histologic hallmark of sarcoidosis and helps distinguish it from infections like tuberculosis.

Does sarcoidosis only affect the lungs?

No. Although the lungs and intrathoracic lymph nodes are most commonly involved, sarcoidosis is a multisystem disease that can affect the skin, eyes, heart, nervous system, and other organs.